Last $1.40 USD
Change Today +0.01 / 0.72%
Volume 126.3K
ONCY On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 8:10 PM 07/30/14 All times are local (Market data is delayed by at least 15 minutes).

oncolytics biotech inc (ONCY) Snapshot

Open
$1.41
Previous Close
$1.39
Day High
$1.42
Day Low
$1.36
52 Week High
09/9/13 - $3.50
52 Week Low
05/9/14 - $1.20
Market Cap
122.0M
Average Volume 10 Days
183.1K
EPS TTM
--
Shares Outstanding
87.1M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ONCOLYTICS BIOTECH INC (ONCY)

oncolytics biotech inc (ONCY) Related Bloomberg News

View More Bloomberg News

oncolytics biotech inc (ONCY) Related Businessweek News

No Related Businessweek News Found

oncolytics biotech inc (ONCY) Details

Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.

oncolytics biotech inc (ONCY) Top Compensated Officers

Executive Chairman, Chief Executive Officer a...
Total Annual Compensation: C$530.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: C$280.0K
Chief Operating Officer and Director
Total Annual Compensation: C$365.0K
Chief Safety Officer and Senior Vice Presiden...
Total Annual Compensation: C$331.9K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $271.2K
Compensation as of Fiscal Year 2013.

oncolytics biotech inc (ONCY) Key Developments

Oncolytics Biotech Inc. Announces Completion of Patient Enrollment in U.S. Randomized Phase II Pancreatic Cancer Study

Oncolytics Biotech Inc. announced completion of patient enrollment in a two-arm randomized phase II study of carboplatin, paclitaxel plus REOLYSIN versus carboplatin and paclitaxel alone in the first line treatment of patients with recurrent or metastatic pancreatic cancer (OSU-10045). The principal investigator is Tanios Bekaii-Saab, MD, associate professor and gastrointestinal oncology section chief at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James). The trial is sponsored by the U.S. National Cancer Institute (NCI) through a clinical trials agreement between the Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis and Oncolytics. Oncolytics is providing clinical supplies of REOLYSIN for the study. The study is an open-label, multi-institution, two-arm phase II randomized study of patients with metastatic pancreatic cancer. Patients were randomized to receive either carboplatin, paclitaxel plus REOLYSIN (Arm A) or carboplatin and paclitaxel alone (Arm B). Patients in both arms received treatment every three weeks (21-day cycles) and standard intravenous doses of paclitaxel and carboplatin on day one only. In Arm A, patients also received intravenous REOLYSIN at a dose of 3x1010 TCID50 on days one through five. Tumor response assessment was done by computed tomography (CT) scan and conducted every eight weeks. Patients who progressed on carboplatin and paclitaxel (Arm B) had REOLYSIN added. If patients experienced significant toxicity related to carboplatin and/or paclitaxel, they could continue with single agent REOLYSIN. The primary objective of the trial is to assess improvement in progression-free survival with REOLYSIN, carboplatin and paclitaxel relative to carboplatin and paclitaxel alone in patients with metastatic pancreatic cancer. The primary endpoint is progression free survival in both arms. Secondary endpoints include overall response rate and overall survival. The study enrolled 70 evaluable patients at test centers across the United States.

Oncolytics Biotech Inc. Elects Linda Hohol and Angela Holtham as Directors

Oncolytics Biotech Inc. elected Linda Hohol and Angela Holtham as directors of the company at the Annual Meeting of Shareholders held on June 18, 2014.

Oncolytics Biotech Inc. - Shareholder/Analyst Call

To discuss the recent progress in the development of REOLYSIN as a potential cancer therapeutic

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ONCY:US $1.40 USD +0.01

ONCY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ONCY.
View Industry Companies
 

Industry Analysis

ONCY

Industry Average

Valuation ONCY Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOLYTICS BIOTECH INC, please visit www.oncolyticsbiotech.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.